Insights

Loading spinner
Gathering insights about GlobeImmune, Inc.

GlobeImmune, Inc. Tech Stack

GlobeImmune, Inc. uses 8 technology products and services including WordPress, MySQL, Twemoji, and more. Explore GlobeImmune, Inc.'s tech stack below.

  • WordPress
    Content Management System
  • MySQL
    Database
  • Twemoji
    Font Scripts
  • Font Awesome
    Font Scripts
  • jQuery
    Javascript Libraries
  • jQuery Migrate
    Javascript Libraries
  • Google Analytics
    Web Analytics
  • Apache
    Web Servers

GlobeImmune, Inc.'s Email Address Formats

GlobeImmune, Inc. uses at least 1 format(s):
GlobeImmune, Inc. Email FormatsExamplePercentage
First.Last@globeimmune.comJohn.Doe@globeimmune.com
39%
FLast@globeimmune.comJDoe@globeimmune.com
21%
Last@globeimmune.comDoe@globeimmune.com
1%
First.Last@globeimmune.comJohn.Doe@globeimmune.com
39%

Frequently Asked Questions

Where is GlobeImmune, Inc.'s headquarters located?

Minus sign iconPlus sign icon
GlobeImmune, Inc.'s main headquarters is located at Louisville, Colorado 80027 US. The company has employees across 1 continents, including North America.

What is GlobeImmune, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact GlobeImmune, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is GlobeImmune, Inc.'s stock symbol?

Minus sign iconPlus sign icon
GlobeImmune, Inc. is a publicly traded company; the company's stock symbol is GBIM.

What is GlobeImmune, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
GlobeImmune, Inc.'s official website is globeimmune.com and has social profiles on LinkedInCrunchbase.

What is GlobeImmune, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
GlobeImmune, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does GlobeImmune, Inc. have currently?

Minus sign iconPlus sign icon
As of October 2025, GlobeImmune, Inc. has approximately 12 employees across 1 continents, including North America. Key team members include Founder Vice President Of Research: A. F.Executive Director Clinical Development: A. C.Director Information Technolog: C. C.. Explore GlobeImmune, Inc.'s employee directory with LeadIQ.

What industry does GlobeImmune, Inc. belong to?

Minus sign iconPlus sign icon
GlobeImmune, Inc. operates in the Biotechnology Research industry.

What technology does GlobeImmune, Inc. use?

Minus sign iconPlus sign icon
GlobeImmune, Inc.'s tech stack includes WordPressMySQLTwemojiFont AwesomejQueryjQuery MigrateGoogle AnalyticsApache.

What is GlobeImmune, Inc.'s email format?

Minus sign iconPlus sign icon
GlobeImmune, Inc.'s email format typically follows the pattern of First.Last@globeimmune.com. Find more GlobeImmune, Inc. email formats with LeadIQ.

How much funding has GlobeImmune, Inc. raised to date?

Minus sign iconPlus sign icon
As of October 2025, GlobeImmune, Inc. has raised $392K in funding. The last funding round occurred on Mar 12, 2014 for $392K.

GlobeImmune, Inc.

Biotechnology ResearchColorado, United States11-50 Employees

We are a biopharmaceutical company established in 1995 focused on developing products for the treatment of cancer and infectious diseases based on our proprietary Tarmogen ® platform. Tarmogens activate the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines which predominately stimulate antibody production. We believe that our Tarmogen platform has applicability to a number of diseases, and may enable us to develop a broad portfolio of products. We have four Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications.

Tarmogens target the molecular profile that distinguishes a diseased cell from a normal cell. We have designed Tarmogens to target specific intracellular and extracellular proteins, or antigens, that play a role in oncology and infectious diseases which represent unmet medical needs. Collaborations with biopharmaceutical companies and research institutions have allowed us to advance the development of a number of our product candidates while managing our own research and development expenses relating to these product candidates.

We have two strategic collaborations with leading biotechnology companies. In October 2011, Gilead Sciences, Inc., exclusively licensed product candidates intended to treat chronic hepatitis B virus, or HBV, infection. Celgene Corporation entered into a collaboration and option agreement for certain oncology product candidates in May 2009. Under this agreement, in July 2013 Celgene exercised its option for a worldwide, exclusive license to the GI-6300 program, which is a Tarmogen program targeting the brachyury protein. Brachyury plays a role in the metastatic spread of certain cancers and is believed to be fundamental in the formation of chordomas, rare bone tumors of the spine. Through June 30, 2014, we have received over $60 million from these collaborations.

Section iconCompany Overview

Headquarters
Louisville, Colorado 80027 US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
GBIM
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $392K

    GlobeImmune, Inc. has raised a total of $392K of funding over 9 rounds. Their latest funding round was raised on Mar 12, 2014 in the amount of $392K.

  • $1M$10M

    GlobeImmune, Inc.'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $392K

    GlobeImmune, Inc. has raised a total of $392K of funding over 9 rounds. Their latest funding round was raised on Mar 12, 2014 in the amount of $392K.

  • $1M$10M

    GlobeImmune, Inc.'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.